Novartis treatment QAB149 found to improve lung function

Novartis has announced the completion of a phase II trial into its investigational bronchodilator QAB149 (indacaterol).

The study showed that the investigational once-daily bronchodilator, which is designed for use in those suffering from chronic obstructive pulmonary disease (COPD), significantly improves lung function.

It was found to bring about a noticeable reduction in breathlessness when compared to the existing treatment option, tiotropium.

Furthermore, COPD patients taking the drug experienced 20 per cent more days in which they did not require relief medication for their symptoms.

Trevor Mundel, global head of development at Novartis, said: “QAB149 has the potential to be recognised as the best bronchodilator for COPD by providing patients with significantly greater lung function improvement and reductions in breathlessness compared to other bronchodilators.”

Meanwhile, a trial into Novartis’ MF59 adjuvanted cell culture-based H1N1 vaccine last week found that it provokes strong immunity in those receiving it.